BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

...in a series B financing led by Venrock Healthcare Capital Partners. Other new investors participating included Acuta Capital Partners...
BioCentury | Feb 12, 2021
Finance

Public listing, Phase II cancer readouts in Cyteir’s sights as it banks $80M crossover round

...validates our approach and our science.”Joining RA Capital in the round were Janus Henderson Investors, Acuta Capital Partners...
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...Elliott Advisors Ltd. affiliate of Elliott Management Corp. TARGETSTSLP – Thymic stromal lymphopoietin BC Staff CG0070 HTD1801 Locanabio Inc. Vida Ventures RA Capital Management Invus Acuta Capital Partners SVB...
Items per page:
1 - 3 of 3
BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

...in a series B financing led by Venrock Healthcare Capital Partners. Other new investors participating included Acuta Capital Partners...
BioCentury | Feb 12, 2021
Finance

Public listing, Phase II cancer readouts in Cyteir’s sights as it banks $80M crossover round

...validates our approach and our science.”Joining RA Capital in the round were Janus Henderson Investors, Acuta Capital Partners...
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...Elliott Advisors Ltd. affiliate of Elliott Management Corp. TARGETSTSLP – Thymic stromal lymphopoietin BC Staff CG0070 HTD1801 Locanabio Inc. Vida Ventures RA Capital Management Invus Acuta Capital Partners SVB...
Items per page:
1 - 3 of 3